Perspective Therapeutics Receives European Commission Orphan Designation For VMT-ฮฑ-NET To Treat Gastroenteropancreatic Neuroendocrine Tumors
Perspective Therapeutics Inc CATX
$2.91
โผ -2.68%
($-0.08)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$3.00
Prev Close
$2.99
Day Range
$2.83 โ $3.04
52W Range
$1.96 โ $6.16
Market Cap
$331.87M
Beta
1.77
EPS (TTM)
$-1.40
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2002-05-31 |
| Shares Out. | 114,050,000 |
| Website | perspectivetherapeutics.com/ โ |
| Phone | 18009279800 |
| Employees | 166 |
| Revenue | $76,000 |
| Gross Profit | $76,000 |
| Net Income | -$26.2M |
| Free Cash Flow | -$107.4M |
| Total Assets | $410.8M |
| Total Liabilities | $63.3M |
| Equity | $347.4M |
About Perspective Therapeutics Inc
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Perspective Therapeutics Inc is a publicly traded company under the ticker symbol CATX on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
20 analysts (2026-07-01)